Summary
The achievable concentrations of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl-3-nitrosourea (ACNU), adriamycin, mitomycin C, vindesine, and epipodophyllotoxin suppressed the natural killer (NK) activity of human peripheral blood lymphocytes in vitro, whereas NK activity was not decreased 24h after incubation with the maximum achievable concentration of cisplatin (cDDP). NK activity of patients treated with 80 mg per square meter of cDDP alone was not decreased for 3 weeks after cDDP administration. In contrast, NK activity of patients treated with the same dose of cDDP and methylprednisolone was significantly decreased 1 week after cDDP administration. It was concluded that methylprednisolone, used as an antiemetic agent, had an immunosuppressive effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 [Suppl 97]:77
Cox WI, Holbrook NJ, Friedman H (1983) Mechanism of glucocorticoid action on murine natural killer activity. J Natl Cancer Inst 71:973–981
Gralla RJ, Casper ES, Kelson DP, Braun DW, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 95:414–420
Habu S, Fukumi H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N (1981) In vivo effects of antiasialo GM1: 1. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127:34–38
Hanna N, Burton RC (1981) Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J Immunol 127:1754–1758
Herbermann RB (1981) Natural killer (NK) cells. Prog Clin Biol Res 58:33–43
Herbermann RB, Ortaldo JR (1981) Natural killer cells: their role in defenses against disease. Science 214:24–30
Hochman PS, Cudkowicz G (1979) Suppression of natural cytotoxicity by spleen cells of hydrocortisone-treated mice. J Immunol 123:968–976
Holbrook NJ, Cox WI, Horner HC (1983) Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation. Cancer Res 43:4019–4025
Mantovani A, Luini W, Peri G, Vecchi A, Spreafico F (1978) Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 61:1255–1261
Moore M, Potter MR (1980) Enhancement of human natural cell-mediated cytotoxicity by interferon. Br J Cancer 41:378
Oshimi K, Gonda N, Sumiga M, Kano S (1980) Effects of corticosteroids on natural killer activity in systemic lupus erythematosus. Clin Exp Immunol 40:83–88
Saijo N, Irimajiri N, Ozaki A, Takizawa T, Beppu Y, Shibuya M, Shimizu E (1982a) Effects of BCG and cyclophosphamide on the spontaneous and antibody-dependent cell-mediated cytotoxicity of peritoneal and spleen lymphocytes of ACI/N rats. Gann 73:270–277
Saijo N, Shimizu E, Irimajiri N, Ozaki A, Kimura K, Takizawa T, Niitani H (1982b) Analysis of natural killer activity and antibody-dependent cellular cytotoxicity in healthy volunteers and in patients with primary lung cancer and metastatic pulmonary tumors. J Cancer Res Clin Oncol 102:195–214
Saijo J, Shimizu E, Shibuya M, Irimajiri N, Takizawa T, Eguchi K, Shinkai T, Tominaga K, Shimabukuro Z, Taniguchi T, Hoshi A (1982c) Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung. Br J Cancer 46:180–189
Saijo N, Ozaki A, Beppu Y, Takahashi K, Shimizu E, Takizawa T, Hoshi A (1984) Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by antiasialo GMl antibody or anticancer agents. J Cancer Res Clin Oncol 107:157–163
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takahashi, K., Saijo, N., Kimata, M. et al. Suppression of natural killer activity in patients treated with cisplatin and methylprednisolone. J Cancer Res Clin Oncol 109, 78–81 (1985). https://doi.org/10.1007/BF01884259
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01884259